Sanofi Global Health announced the introduction of Impact®, a new brand of Sanofi's standard-of-care medications intended for charitable distribution to vulnerable populations in the world's poorest nations.
The secure distribution of 30 Sanofi medications in 40 lower-income nations will be made possible by the Impact® brand, which also contains insulin, glibenclamide, and oxaliplatin among other medications.
The drugs cover a wide range of treatment areas, including diabetes, cardiovascular disease, tuberculosis, malaria, and cancer, and are regarded as essential by the World Health Organization.
Sanofi - It is a company, a cutting-edge global healthcare organization, with a single goal: to use science's wonders to enhance people's lives. Our teams work to change the way medication is delivered to patients by making the seemingly impossible feasible.
1) The availability of medication, including insulin, in 40 lower-income nations.
2) Fund for investments created to support the development of sustainable health systems.
3)As global health players assemble in Paris, announcements are made.
The drugs cover a wide range of treatment areas, including diabetes, cardiovascular disease, tuberculosis, malaria, and cancer, and are regarded as essential by the World Health Organization.
The introduction of the Impact® brand is one of the actions made since Sanofi Global Health was established last year. This nonprofit division of the business aims to improve access to healthcare by distributing medications and establishing regional healthcare infrastructures.
Sanofi Worldwide Health is the first and only global program to offer access to such a wide range of medications in so many nations and across so many therapeutic areas, all while funding a regional assistance program and fostering regional inclusive enterprises.
The business also announced the creation of an impact fund that will assist entrepreneurs and other creative thinkers who can offer scalable solutions for long-term healthcare in neglected areas. The fund will promote the GHU aim of leveraging global, regional, and local investment to support the training of healthcare professionals and assisting communities in managing sustainable care systems by offering inclusive enterprises financing and technical help.
In order to successfully reach, treat, and manage patients' health, Sanofi has gathered important global health players to explore how to develop end-to-end health initiatives that are anchored in the communities they serve.
One of the three components of Sanofi's multi-tiered approach to social impact, which also includes a CSR strategy integrated into our commercial operations and the Foundation S, the Sanofi group committed to philanthropy, is Sanofi Global Health:
• The mission of Foundation S is to combat pediatric cancer, improve the health of those most impacted by climate change, and make product donations to address humanitarian emergencies. Sanofi has also pledged to providing 100,000 vials annually, free of charge, to help patients with five different lysosomal storage diseases (LSD's), a category of uncommon hereditary ailments brought on by enzyme deficiencies. This commitment continues the company's 30-year tradition.
• Our organization-wide CSR strategy is built on four pillars: responsible business, affordable access, innovation for at-risk communities, and planet care. It is based around flagship initiatives that span the whole value chain of the business, from R&D to manufacturing to commercial operations, taking into account the reality that every aspect of the organization has a part to play and something to offer.
You must be logged in to post a comment.